Ketamine: all studies (page 249) - The Consciousness Library

Ketamine modulates aggressive behavior in adult zebrafish.

Neuroscience Letters September 25, 2018 Paula Michelotti, Vanessa A Quadros, Maria E Pereira et al.

Ketamine is a non-competitive glutamatergic antagonist that induces analgesia and anesthesia. Although ketamine displays anxiolytic and antidepressant properties, it may induce pro-psychosis and hallucinogen effects, as well as stereotypic behaviors following acute administration at sub-anesthetic doses. Since heightened aggression is maladaptive and may comorbid with various neuropsychiatric...

DOI: 10.1016/j.neulet.2018.08.009 Full text Ketamine Aggressive behavior Psychotomimetic drugs Stereotypic behaviors +1

Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study

The British Journal of Psychiatry September 24, 2018 Yoav Domany, Maya Bleich‐Cohen, Ricardo Tarrasch et al. 117 citations

BACKGROUND: Ketamine has been demonstrated to improve depressive symptoms.AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients with treatment-resistant depression (TRD). METHOD: In a randomised, double-blind, placebo-controlled, proof-of-concept trial, 41 participants received either 1 mg/kg oral ketamine or placebo thrice weekly for 21 days...

DOI: 10.1192/bjp.2018.196 Full text

Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors

International Journal of Molecular Sciences September 23, 2018 Domenico de Berardis, Michele Fornaro, Alessandro Valchera et al. 171 citations

Despite the continuous advancement in neurosciences as well as in the knowledge of human behaviors pathophysiology, currently suicide represents a puzzling challenge. The World Health Organization (WHO) has established that one million people die by suicide every year, with the impressive daily rate of a suicide every 40 s. The weightiest concern about suicidal behavior is how difficult it is...

DOI: 10.3390/ijms19102888 Ketamine Anxiety Suicidal ideation Mood disorders +5

On the safety of repeated ketamine infusions for the treatment of depression: Effects of sex and developmental periods

Neurobiology of Stress September 21, 2018 Caroline E. Strong, Mohamed Kabbaj 60 citations

In this review, we will discuss the safety of repeated treatments with ketamine for patients with treatment-resistant depression (TRD), a condition in which patients with major depression do not show any clinical improvements following treatments with at least two antidepressant drugs. We will discuss the effects of these treatments in both sexes at different developmental periods. Numerous...

DOI: 10.1016/j.ynstr.2018.09.001

Synthesis of carbon-14 labeled ketamine and norketamine.

Journal of Labelled Compounds and Radiopharmaceuticals September 2018 Lu Chen, Yong Gong, Rhys Salter

Ketamine is a well-known general anesthetic that inhibits cerebral NMDA receptors. Norketamine is a major circulating metabolite of this drug. A nasal spray formulation of esketamine, the S enantiomer of ketamine, is under development for the management of treatment-resistant depression. To assess the pharmacokinetic properties, C-14 labeled ketamine and norketamine were prepared separately...

DOI: 10.1002/jlcr.3669 Full text C-14 labeled Nmda receptors Noresketamine Norketamine +1

Agmatine potentiates neuroprotective effects of subthreshold concentrations of ketamine via mTOR/S6 kinase signaling pathway.

Neurochemistry International September 2018 Mauren K Tavares, Suellen Dos Reis, Nicolle Platt et al.

Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is one of the most robust neurobiological findings in the pathophysiology of major depressive disorder (MDD) over the last 40 years. The persistent increase in glucocorticoids levels induces morphological and anatomical changes in the brain, especially in the hippocampus. Ketamine represents a major advance for the treatment of MDD,...

DOI: 10.1016/j.neuint.2018.05.006 Full text Ketamine Agmatine Akt Ht22 +3

(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.

Neuropharmacology September 1, 2018 Dylan Chou, Hsien-Yu Peng, Tzer-Bin Lin et al.

It has been widely reported that ketamine rescues chronic stress-induced depression-like behavior, but the underlying cellular mechanisms of the rapid antidepressant actions of ketamine remain largely unclear. Both male and female Sprague-Dawley rats were used and received modified learned helplessness paradigm to induce depression-like behavior. Depression-like behavior was assayed and...

DOI: 10.1016/j.neuropharm.2018.06.033 Full text Depression Ampa receptor Chronic stress Electrophysiology +1

Subanesthetic ketamine reverses neuronal and astroglial metabolic activity deficits in a social defeat model of depression.

Journal of Neurochemistry September 2018 Pravin K Mishra, Arvind Kumar, Kevin L. Behar et al.

Depression is one of the most debilitating neuropsychiatric disorders. Most of the current antidepressants have long remission time and low recovery rate. This study explores the impact of ketamine on neuronal and astroglial metabolic activity in prefrontal cortex in a social defeat (SD) model of depression. C57BL/6 mice were subjected to a social defeat paradigm for 5 min a day for 10...

DOI: 10.1111/jnc.14544 Full text Glutamate Glutamine Neuron-glia interaction Neurotransmission +1

Intravenous Ketamine for Adolescents with Treatment-Resistant Depression: An Open-Label Study.

Journal of Child and Adolescent Psychopharmacology September 2018 Kathryn R. Cullen, Palistha Amatya, Mark G Roback et al.

Novel interventions for treatment-resistant depression (TRD) in adolescents are urgently needed. Ketamine has been studied in adults with TRD, but little information is available for adolescents. This study investigated efficacy and tolerability of intravenous ketamine in adolescents with TRD, and explored clinical response predictors. Adolescents, 12-18 years of age, with TRD (failure to...

DOI: 10.1089/cap.2018.0030 Full text Depression Ketamine Adolescent Treatment-resistant

Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine.

Pharmacology, Biochemistry, and Behavior September 2018 Zheng Tian, Chao Dong, Atsuhiro Fujita et al.

The N-methyl-d-aspartate receptor (NMDAR) antagonist (R,S)-ketamine has robust antidepressant effects in depressed patients although it has detrimental side effects such as psychotomimetic and dissociative symptoms. (R,S)-Ketamine is known to cause the expression of heat shock protein HSP-70 (a marker for neuronal injury) in the retrosplenial cortex of rat brain, suggesting that the...

DOI: 10.1016/j.pbb.2018.07.003 Full text R-ketamine S-ketamine Heat shock protein Neurotoxicity +1

Research